CymaBay Therapeutics Announces Oral Late-Breaking Presentation of Positive Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement